卵胞刺激ホルモンの世界市場-2023-2030

市場概要

卵胞刺激ホルモンの世界市場は、2022年に19億米ドルに達し、2030年には最大で29億米ドルに達することで有利な成長を示すと予測されます。卵胞刺激ホルモンの世界市場は、予測期間（2023-2030年）に5.8%のCAGRを示すと予想されています。不妊症の有病率の増加、不妊治療に対する認識と受容の高まり、高齢化人口の増加が、卵胞刺激ホルモン市場動向の成長を後押ししています。

世界の卵胞刺激ホルモン（FSH）市場は、近年、継続的に拡大しています。生殖ホルモンの一種であるFSHは、月経周期の調節や女性の卵巣卵胞の成長を促すのに不可欠です。不妊治療やホルモン補充療法によく利用されています。

世界の卵胞刺激ホルモン市場の範囲は、組換えFSH、尿中FSH、不妊治療、生殖補助技術などを含む構成要素からなり、卵胞刺激ホルモンの市場シェアを増加させています。卵胞刺激ホルモンの世界市場は、不妊治療手順の技術的進歩、不妊治療に対する認識と受容の高まり、生殖医療への注目の高まりなどの要因の結果、拡大しつつあります。

市場力学

高齢化社会の進展が卵胞刺激ホルモン市場の成長を牽引

世界のFSH市場は、人口の高齢化によって牽引されています。個人の生殖能力は加齢とともに低下し、その結果、加齢に伴う不妊に対処するための不妊治療、特にFSH治療に対する需要が高まっています。不妊治療に対する理解や受容性の向上、出産延期の動向などが、市場の上昇に寄与しています。

例えば、世界保健機関（WHO）の2022年報告によると、2030年には地球上の約6人に1人が60歳以上の高齢者になると言われています。この期間内に、60歳以上の世界人口に占める割合は、2020年の10億人から14億人に増加すると予想されています。全体として、高齢化社会の親になりたいという願望と不妊治療ソリューションの必要性が、世界の卵胞刺激ホルモン市場の成長を後押ししています。

生殖補助医療技術の採用拡大が卵胞刺激ホルモンの世界市場の主要な促進要因に

生殖補助医療（ART）には、妊娠を達成するために個人を支援するために設計されたさまざまな医療技術が含まれます。体外受精（IVF）は最も有名なARTの1つで、卵子と精子を実験室で混合して受精させ、得られた胚を子宮に移植する方法です。

さらに、多嚢胞性卵巣症候群（PCOS）の増加も不妊症の増加に寄与しています。PCOSは女性の不妊症の原因としてよく知られており、米国疾病予防管理センター（CDC）の2022年の統計によると、米国の生殖年齢にある女性のおよそ6％から12％が発症しています。PCOSの継続的な普及は、不妊治療に対する需要を促進し、結果として予測期間中、世界の卵胞刺激ホルモン市場を促進することになります。

不妊症の問題や生殖補助医療の必要性による個人への多大な感情的・心理的負担は、市場の成長を妨げます。

不妊症やARTがもたらす心理社会的影響は広範囲に及び、患者の自己同一性や個人的主体性の感覚、精神的幸福、性的・夫婦的関係、生殖効率、治療遵守、妊娠転帰に大きな影響を与える可能性があります。ARTを受けている女性の25％から65％が、臨床的ストレス、不安、自尊心の低下や罪悪感などのネガティブな感情を経験しています。したがって、上記のような要因が卵胞刺激ホルモン市場の成長を制限しているのです。

COVID-19の影響分析

COVID-19のパンデミックと世界各国での封鎖により、あらゆる業種の企業の財務的健全性が影響を受けています。そのため、COVID-19の公衆衛生上の緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーや研究者を支援し、試験参加者の安全を確保し、適正臨床実施（GCP）を遵守し、試験の完全性に対するリスクを最小化するための一般的配慮を含むガイドラインを発表しました。

ロシア・ウクライナ紛争影響分析

ロシアとウクライナの紛争は、サプライチェーンの中断、不確実性、不安定性を引き起こす可能性があり、世界の卵胞刺激ホルモン（FSH）市場に影響を与える可能性があります。FSHの製品開発と臨床試験に影響が及び、技術革新が遅れる可能性があります。市場参入企業は、FSHの生産多様化や代替ソースを探すかもしれません。

さらに、価格と需要は、為替変動や市場力学の変化を含む経済的影響によって影響を受ける可能性があります。また、地域差もあり、紛争に近い国ほど、その影響をすぐに感じるかもしれません。FSH市場で潜在的な障害を克服し、可能性をつかむために、利害関係者は常に観察し、柔軟性を維持する必要があります。

目次

第1章 調査手法とスコープ

• 調査手法
• 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 高齢化人口の増加
    • 生殖補助医療技術の採用拡大
  • 抑制要因
    • 不妊の問題別精神的・心理的負担
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 法規制の分析

第6章 COVID-19の分析

第7章 タイプ別

• リコンビナントFSH
• 尿中FSH

第8章 アプリケーション別

• 不妊治療
• 生殖補助医療（ART）
• その他

第9章 エンドユーザー別

• 不妊治療センター
• 病院
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 競合シナリオ
• 市況ポジショニング/シェア分析
• M&A（合併・買収）分析

第12章 企業プロファイル

• Merck Serono
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展状況
• Creative BioMart
• Midas Pharma GmbH
• GenPharm
• Trumac Healthcare
• Livzon
• Shanghai Techwell Biopharmaceutical Co., Ltd.
• Merck Sharp & Dohme Corp
• Lee Biosolutions,Inc
• BIOGENIX INC.PVT.LTD.

第13章 付録

Market Overview

The Global Follicle Stimulating Hormone Market reached US$ 1.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.9 billion by 2030. The global follicle stimulating hormone market is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030). The increasing prevalence of infertility, growing awareness and acceptance of fertility treatments, and growing aging population are driving the growth of the follicle stimulating hormone market trends.

The global follicle stimulating hormone (FSH) market has been expanding continuously in recent years. FSH, a reproductive hormone, is essential in regulating the menstrual cycle and encouraging the growth of ovarian follicles in women. It is commonly utilized in fertility treatments and hormone replacement therapies.

The global follicle stimulating hormone market scope comprises components encompassing recombinant FSH, urinary FSH, infertility treatment, assisted reproductive technology and others, which has increased usage of follicle stimulating hormone market share. The global market for follicle stimulating hormones is expanding as a result of factors including technological advancements in fertility treatment procedures, increasing awareness and acceptance of fertility treatments, and increasing focus on reproductive health.

Market Dynamics

An Increase in Aging Population Drive the Growth of the Follicle Stimulating Hormone Market

The global FSH market is being driven by an aging population. Individuals' fertility potential reduces as they age, resulting in an increased demand for fertility treatments, especially FSH treatment, to address age-related infertility. The increased understanding and acceptability of fertility treatments, as well as the trend of postponed childbirth, have all contributed to the market's rise.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. Overall, the aging population's desire for parenthood and the need for fertility solutions drive the growth of the global follicle stimulating hormone market.

Growing Adoption of Assisted Reproductive Technology is the Major Driver in the Global Follicle Stimulating Hormone Market

The use of assisted reproductive technology (ART) includes a variety of medical techniques designed to aid individuals in achieving pregnancy. In vitro fertilization (IVF) is one of the most well-known types of ART, in which eggs and sperm are mixed in a laboratory setting to fertilize and then implant the resulting embryos into the uterus.

Furthermore, the rising prevalence of polycystic ovary syndrome (PCOS) has contributed to an increase in infertility. PCOS is a common cause of female infertility, affecting roughly 6% to 12% of women of reproductive age in the United States, according to the Centers for Disease Control and Prevention (CDC) 2022 statistics. The continued prevalence of PCOS will drive demand for infertility treatments, consequently propelling the global follicle stimulating hormone market over the forecast period.

Significant Emotional and Psychological Toll on Individuals Due to Fertility Challenges and the Need for Assisted Reproductive Technologies Will Hamper the Growth of the Market.

The psychosocial consequences of infertility and ART are extensive, and they can have a significant impact on patients' sense of self-identity and personal agency, mental well-being, sexual and marital relationships, reproductive efficiency, treatment compliance, and pregnancy outcomes. Between 25% and 65% of women receiving ART experience clinical stress, anxiety, and negative emotions such as low self-esteem or guilt. Hence, the above mentioned factors are limiting the follicle stimulating hormone market's growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The conflict between Russia and Ukraine has the potential to cause supply chain interruptions, uncertainty, and instability, which could affect the worldwide follicle-stimulating hormone (FSH) market. FSH product development and clinical trials would be impacted, which would slow down innovation. Market participants might look for FSH production diversification and alternate sources.

Furthermore, pricing and demand may be impacted by the economic impact, which includes currency fluctuations and modifications to market dynamics. There may be regional variances, with nations closer to the conflict feeling the effects more immediately. In order to navigate potential obstacles and seize possibilities in the FSH market, industry stakeholders must maintain constant observation and flexibility.

Segment Analysis

The global follicle stimulating hormone market is segmented based on type, application, end user, and region.

Recombinant FSH Segment Accounts for 56.3% of the Market Share Owing to Rising Demand for it.

Recombinant FSH products are produced in the laboratory and have various advantages over urinary-derived FSH products. One significant advantage is their superior purity, as they are free of contaminants commonly present in urinary-derived FSH. This provides consistent potency and reduces the possibility of contamination.

Gonal-f, Follistim, and Puregon are examples of rFSH medicines that have a sizable market share. Because of their effectiveness and high-quality standards, these brands have gained favor among healthcare providers and patients. They are trusted choices in reproductive treatments, including regulated ovarian stimulation in ART procedures such as IVF.

For instance, Bharat Serums and Vaccines Limited is conducting a clinical trial using Recombinant Human Follicle Stimulating Hormone for treating infertility. About 250 women in the age group of 20 to 39 years have participated in this trial and currently, it is in phase 3 trial and the estimated completion of the trial is in November 2023. Therefore, owing to the above reasons, the recombinant FSH segment is expected to drive the market growth over the forecast period.

Geographical Analysis

North America Accounted for Approximately 41.4% of the Market Share Owing to the Investment by the Major Players' Presence in this Region

North America's market dominance has been facilitated by the presence of established and influential companies, increased awareness and an increase in the rate of infertility growth which is related to unhealthy lifestyles and diets. Also, the rising healthcare costs and the widespread use of FSH products, along with an increase in inpatient visits to gynecologists are driving the market demand in North America.

Furthermore, Fertility Awareness Methods (FAMs), for example, are recognized by the United States Agency for International Development (USAID) as modern contraceptives that meet specified requirements, such as safety, effectiveness in preventing conception, and a basic grasp of reproductive biology.

FAMs have been evaluated in well-designed studies to determine their efficacy under a variety of situations. FAMs also have the advantage of not requiring clinical involvement and can be delivered through a variety of service delivery methods. As a result of the aforementioned factors, the North American region is expected to hold the biggest market share throughout the projection period.

Competitive Landscape

The major global players in the follicle stimulating hormone market include: Merck Serono, Creative BioMart, Midas Pharma GmbH, GenPharm, Trumac Healthcare, Livzon, Shanghai Techwell Biopharmaceutical Co., Ltd., Merck Sharp & Dohme Corp, Lee Biosolutions, Inc, and BIOGENIX INC.PVT.LTD.

Why Purchase the Report?

• To visualize the global follicle stimulating hormone market segmentation based on type, application, end user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Follicle stimulating hormone market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global follicle stimulating hormone market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Application
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. An Increase in Aging Population
    • 4.1.1.2. Growing Adoption of Assisted Reproductive Technology
  • 4.1.2. Restraints
    • 4.1.2.1. Emotional and Psychological Toll on Individuals due to Fertility Challenges
  • 4.1.3. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Recombinant FSH*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Urinary FSH

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Infertility Treatment*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Assisted Reproductive Technology (ART)
• 8.4. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Infertility Center*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Hospitals
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan

Australia

• 10.5.6.4. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Merck Serono*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Creative BioMart
• 12.3. Midas Pharma GmbH
• 12.4. GenPharm
• 12.5. Trumac Healthcare
• 12.6. Livzon
• 12.7. Shanghai Techwell Biopharmaceutical Co., Ltd.
• 12.8. Merck Sharp & Dohme Corp
• 12.9. Lee Biosolutions,Inc
• 12.10. BIOGENIX INC.PVT.LTD.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us